Walden Group Healthcare M&A Blog

  • Big Pharma Invest Deeper into Cancer Treatment

    In early December 2019, two of the biggest pharmaceutical companies announced multibillion-dollar deals aiming at bolstering their oncology pipeline.   Merck & Co. Inc. is paying $2.5b to acquire ArQule, Inc, whose lead investigational candidate is an oral Bruton’s tyrosine kinase (BTK) inhibitor currently in a Phase II dose-expansion...
    Read More
  • Orthopedic and Spine Sector Consolidations Tighten the Market

    Stryker recently announced purchase of Wright Medical for $4b purchase (4.5x revenue and 38.5x EBITDA) is yet another example of the consolidation within the orthopedic and spine sectors.  As reimbursement levels become tighter and margins are challenged, economies of scale become paramount. Wright Medical is a recognized leader in upper...
    Read More
  • Novartis is paying $9.7b to acquire The Medicines Company for a Potentially Blockbuster Cholesterol-Lowering Therapy

    The Medicines Company is developing "inclisiran",  a potentially transformational medicine that reimagines the treatment of atherosclerotic heart disease and familial hypercholesterolemia. With tens of millions of patients at higher risk of cardiovascular events from high LDL-C, inclisiran could contribute significantly to improved patient...
    Read More
  • The Restart of Medicare Orthotics & Prosthetics Competitive Bidding Program Adds Margin Pressure on O&P Players

    After a pause, The Centers for Medicare & Medicaid Services (CMS) announced plans to reinstate the Competitive Bidding Program for Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies.  “Round 2021” competition will cover a total of 130 competitive bidding areas and add new product categories: off-the-shelf (OTS) back...
    Read More
  • The Coming of Age of Gene Therapy

    In vivo gene therapy, the process of delivering genetic material into the body to cure disease, is a challenging area but has the potential to cure millions suffering from genetic conditions such as cystic fibrosis or muscular dystrophy. With a $40b plus market, gene therapy has the potential to be non-pathogenic to humans and prevent DNA damage...
    Read More